111 related articles for article (PubMed ID: 2332771)
41. Resistance of pokeweed mitogen-stimulated B cells to inhibition by deoxyadenosine.
Hayward AR
Clin Exp Immunol; 1980 Jul; 41(1):141-9. PubMed ID: 6969149
[TBL] [Abstract][Full Text] [Related]
42. Pentostatin and purine analogs for indolent lymphoid malignancies.
Ho AD; Hensel M
Future Oncol; 2006 Apr; 2(2):169-83. PubMed ID: 16563086
[TBL] [Abstract][Full Text] [Related]
43. Dietary supplementation of probiotic Bacillus polyfermenticus, Bispan strain, modulates natural killer cell and T cell subset populations and immunoglobulin G levels in human subjects.
Kim HS; Park H; Cho IY; Paik HD; Park E
J Med Food; 2006; 9(3):321-7. PubMed ID: 17004893
[TBL] [Abstract][Full Text] [Related]
44. Pentostatin (Nipent) in the treatment of chronic lymphocyte leukemia and hairy cell leukemia.
Dillman RO
Expert Rev Anticancer Ther; 2004 Feb; 4(1):27-36. PubMed ID: 14748654
[TBL] [Abstract][Full Text] [Related]
45. Immunomodulatory activities of human leukocyte interferon in advanced cancer patients.
Bash JA; Teitelbaum D; Sreevalsan T; Neefe JR
J Biol Response Mod; 1983; 2(1):57-65. PubMed ID: 6606019
[TBL] [Abstract][Full Text] [Related]
46. Phase I study of YK-176 (2'-deoxycoformycin) in patients with adult T-cell leukemia-lymphoma. The DCF Study Group.
Tobinai K; Shimoyama M; Inoue S; Takayasu S; Mikuni C; Kozuru M; Oda S; Nakajima H
Jpn J Clin Oncol; 1992 Jun; 22(3):164-71. PubMed ID: 1518164
[TBL] [Abstract][Full Text] [Related]
47. Plasma levels of soluble CD8 antigen and interleukin-2 receptor antigen in patients with hairy cell leukemia, relationship with splenectomy and with clinical response to therapy.
Ho AD; Grossmann M; Knauf W; Martin H; Trümper L; Zwingers T; Sonnen R; Pralle H; Hunstein W
Leukemia; 1989 Oct; 3(10):718-23. PubMed ID: 2506398
[TBL] [Abstract][Full Text] [Related]
48. Pentostatin (2prime prime or minute-Deoxycoformycin): Clinical Pharmacology, Role In Cancer Chemotherapy, and Future Prospects.
Spiers AS
Am J Ther; 1995 Mar; 2(3):196-216. PubMed ID: 11847552
[TBL] [Abstract][Full Text] [Related]
49. Long term results with 2'deoxycoformycin in hairy cell leukemia.
Catovsky D; Matutes E; Talavera JG; O'Connor NT; Johnson SA; Emmett E; Corbett L; Swansbury J
Leuk Lymphoma; 1994; 14 Suppl 1():109-13. PubMed ID: 7820041
[TBL] [Abstract][Full Text] [Related]
50. Strenuous exercise and immunological changes: a multiple-time-point analysis of leukocyte subsets, CD4/CD8 ratio, immunoglobulin production and NK cell response.
Shek PN; Sabiston BH; Buguet A; Radomski MW
Int J Sports Med; 1995 Oct; 16(7):466-74. PubMed ID: 8550256
[TBL] [Abstract][Full Text] [Related]
51. Abnormalities of peripheral blood T lymphocytes and natural killer cells in alcoholic hepatitis persist after a 3-month withdrawal period.
Laso FJ; Madruga JI; López A; Ciudad J; Alvarez-Mon M; San Miguel J; Orfao A
Alcohol Clin Exp Res; 1997 Jun; 21(4):672-6. PubMed ID: 9194923
[TBL] [Abstract][Full Text] [Related]
52. Immunosuppressive effects of recombinant interferon-alpha during long-term treatment of cancer patients.
Teichmann JV; Sieber G; Ludwig WD; Ruehl H
Cancer; 1989 May; 63(10):1990-3. PubMed ID: 2702571
[TBL] [Abstract][Full Text] [Related]
53. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse.
Tallman MS; Hakimian D; Kopecky KJ; Wheaton S; Wollins E; Foucar K; Cassileth PA; Habermann T; Grever M; Rowe JM; Peterson LC
Clin Cancer Res; 1999 Jul; 5(7):1665-70. PubMed ID: 10430066
[TBL] [Abstract][Full Text] [Related]
54. [Hairy cell leukemia successfully treated with 2'-deoxycoformycin following refractoriness to splenectomy and alpha-interferon therapy].
Shibata T; Hotta T
Rinsho Ketsueki; 1992 Feb; 33(2):216-20. PubMed ID: 1635172
[TBL] [Abstract][Full Text] [Related]
55. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.
Lauria F; Bocchia M; Marotta G; Raspadori D; Zinzani PL; Rondelli D
Haematologica; 1999 Jan; 84(1):22-5. PubMed ID: 10091389
[TBL] [Abstract][Full Text] [Related]
56. Deoxycoformycin in the treatment of mature B-cell malignancies.
Dearden C; Catovsky D
Br J Cancer; 1990 Jul; 62(1):4-5. PubMed ID: 2390480
[No Abstract] [Full Text] [Related]
57. Difference in effect of single immunosuppressive agents (cyclophosphamide, CCNU, 5-FU) on peripheral blood immune cell parameters and central nervous system immunoglobulin synthesis rate in patients with multiple sclerosis.
Shih WW; Baumhefner RW; Tourtellotte WW; Haskell CM; Korn EL; Fahey JL
Clin Exp Immunol; 1983 Jul; 53(1):122-32. PubMed ID: 6603303
[TBL] [Abstract][Full Text] [Related]
58. Cardiac complications observed in elderly patients following 2'-deoxycoformycin therapy.
Grem JL; King SA; Chun HG; Grever MR
Am J Hematol; 1991 Nov; 38(3):245-7. PubMed ID: 1951329
[TBL] [Abstract][Full Text] [Related]
59. Kinetics of recovery of CD4+ T cells in peripheral blood of deoxycoformycin-treated patients.
Steis RG; Urba WJ; Kopp WC; Alvord WG; Smith JW; Longo DL
J Natl Cancer Inst; 1991 Nov; 83(22):1678-9. PubMed ID: 1684207
[No Abstract] [Full Text] [Related]
60. Administration of monthly pulses of cyclophosphamide in multiple sclerosis patients. Delayed recovery of several immune parameters following discontinuation of long-term cyclophosphamide treatment.
Moody DJ; Fahey JL; Grable E; Ellison GW; Myers LW
J Neuroimmunol; 1987 Mar; 14(2):175-82. PubMed ID: 2950131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
